Close
Pipeline

Accelerated clinical development enabled by global collaborations

Biosyngen focuses on unmet needs in oncology through First-in Class (FIC) products with a differentiated strategy. The company is rare in the industry that simultaneously covers CAR-T, TCR-T, and TIL, all of which have entered the clinical stage, forming a comprehensive and complementary research and development pipeline.

Multiple assets in pre-clinical and clinical development
Product Indication Pre-clinical IIT Phase I Phase II NDA/BLA List
BRG01
Global (First-in-Class) Nasopharyngeal cancer (NPC)EBV+ LymphomaBRG01 in NPC is granted Fast Track Designation by US FDA
53%
48%
BRL03
Global (First-in-Class) Multiple solid tumors (incl. Lung)
40%
BST02
Global (First-in-Class) Liver cancer (all types)BST02 is granted Fast Track Designation by US FDA
40%
BGT007
Global (First-in-Class) CRC, GC, EC & PDAC
25%
GGT008
Global (First-in-Class) BC, CC, OC
15%
Allo-cel
Global (First-in-Class) Multiple solid & liquid tumors
15%
WORK WITH US

Take part in our mission to deliver more effective cancer care and
improve patient outcomes.